文献速递前列腺增生与排尿功能障碍

URO-902(pVAX/hSlo)基因治疗女性膀胱过度活动症与急迫性尿失禁:一项随机2a期试验的安全性与疗效

Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial.
PubMed 文献 · J Urol · 2024-12-18

这项2a期安慰剂对照试验将80例难治性膀胱过度活动症(OAB)伴急迫性尿失禁的女性随机分配至URO-902 24 mg、48 mg或安慰剂单次膀胱逼尿肌内注射。第12周时,两个剂量组每日排尿次数较安慰剂显著改善;48 mg组在急迫发作次数和患者整体变化印象应答率方面也显著优于安慰剂。URO-902总体安全且耐受性良好。

要点

  • 第12周每日排尿次数变化:URO-902 24 mg组−2.3次、48 mg组−2.4次,均优于安慰剂组−0.8次。
  • 48 mg组急迫发作次数变化−3.4次 vs 安慰剂−1.1次,差异有统计学意义(名义P=0.016)。
  • 48 mg组患者整体变化印象应答率58% vs 安慰剂31%(名义P=0.026)。

核心结论

  • 在这项2a期试验中,URO-902治疗在疗效和患者报告结局方面较安慰剂有改善,且安全、耐受性良好。

研究设计与样本

  • 随机、安慰剂对照的2a期试验,纳入80例40至79岁、对OAB药物难治的OAB伴急迫性尿失禁女性。
  • 患者随机接受单次URO-902 24 mg(n=26)、URO-902 48 mg(n=27)或安慰剂(n=27),在局部麻醉下经膀胱镜行逼尿肌内注射。
  • 74例接受治疗,67例完成至第24周随访。

主要发现

  • 第12周每日排尿次数较基线的最小二乘均值变化:URO-902 24 mg组−2.3次、48 mg组−2.4次 vs 安慰剂组−0.8次;最小二乘均值差(95%CI)分别为−1.5(−2.7至−0.3)和−1.6(−2.8至−0.4),名义P分别为0.017和0.009。
  • 第12周急迫发作次数较基线变化:URO-902 48 mg组−3.4次 vs 安慰剂组−1.1次;最小二乘均值差(95%CI)−2.2(−4.0至−0.4),名义P=0.016。
  • 第12周患者整体变化印象应答率:URO-902 48 mg组58% vs 安慰剂组31%,名义P=0.026。
  • 发生至少1次治疗中出现的不良事件的比例:URO-902 24 mg组46%、48 mg组54%、安慰剂组54%;最常见为尿路感染(0%、15%、4%)和血尿(6%、8%、8%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed efficacy and safety of URO-902, an investigational gene therapy expressing the α subunit of the large-conductance Ca2+-activated K+ channel, in a phase 2a placebo-controlled trial in women with overactive bladder (OAB). MATERIALS AND METHODS: Women, age 40 to 79 years, with OAB and urge urinary incontinence who were refractory to OAB medications were randomized to single-dose URO-902 24 and 48 mg or placebo administered by intradetrusor injection via cystoscopy under local anesthesia. Efficacy end points included change from baseline to week 12 in mean daily micturitions, urgency episodes, urge urinary incontinence episodes, and patient-reported outcomes. Safety assessments included adverse events and postvoid residual urine volume. RESULTS: Of 80 patients randomized (URO-902 24 mg, n = 26; URO-902 48 mg, n = 27; placebo, n = 27), 74 received treatment, and 67 reached week 24. At week 12, URO-902 24 and 48 mg were associated with significant improvement vs placebo in daily micturitions (least-squares mean change from baseline, -2.3 and -2.4 vs -0.8, respectively; least-squares mean difference [95% CI], ‒1.5 [‒2.7 to ‒0.3] and ‒1.6 [‒2.8 to ‒0.4], nominal P = .017 and P = .009, respectively). URO-902 48 mg was associated with significant improvements vs placebo in urgency episodes (‒3.4 vs ‒1.1; ‒2.2 [‒4.0 to ‒0.4]; nominal P = .016) and percentage of Patient Global Impression of Change responders (58% vs 31%; nominal P = .026). Among patients receiving URO-902 24 mg, URO-902 48 mg, and placebo, 46%, 54%, and 54%, respectively, experienced ≥ 1 treatment-emergent adverse events, most commonly UTI (0%, 15%, 4%) and hematuria (6%, 8%, 8%). CONCLUSIONS: In this phase 2a trial, treatment with URO-902 was associated with improvements vs placebo in efficacy and patient-reported outcomes and was safe and well tolerated.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Enemchukwu EA, Kalota S, Robertson K, et al. Gene Therapy With URO-902 (pVAX/hSlo) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a Trial. J Urol. 2024. PMID: 39693268. doi:10.1097/JU.0000000000004373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。